title: Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients.
abstract: This study was a non-comparative multicenter clinical trial to evaluate the efficacy and tolerability of itraconazole oral solution 200 mg/day (100 mg twice a day in the fasting state) for the treatment of oropharyngeal candidiasis in AIDS patients. We included 50 patients who were treated and followed for up to 3 weeks after ending therapy in the analysis. Mycological cures at the end of therapy occurred in 20/50 patients (40%), but colonization by Candida sp. was recorded in 42/50 (84%) by the end of follow-up. A high rate of clinical response was observed in 46/50 (92%), and the response was sustained for up to 21 days after stopping therapy in 24/46 patients (52%). Clinical relapses were documented among 22 patients, but all causative fungal organisms associated with a relapse were susceptible to itraconazole. There were many patients with persistence or recurrence of Candida, but without mucositis. Relapse of Candida mucositis was significantly related to low levels of CD(4) lymphocytes exhibited by symptomatic patients. The drug was well tolerated by all but 1 patient. We conclude that itraconazole oral solution (100 mg bid for 7-14 days) is a well tolerated and effective treatment for suppressing the symptoms of oropharyngeal candidiasis in AIDS patients. Patients with severe immunosuppression may relapse and require frequent cycles of treatment or longterm suppressive therapy.
authors.affiliation: Clinical Hospital, Federal University of Paraná, Curitiba, Brazil.
authors.forename: F
authors.initials: F
authors.lastname: Queiroz-Telles
authors.forename: N
authors.initials: N
authors.lastname: Silva
authors.forename: M M
authors.initials: MM
authors.lastname: Carvalho
authors.forename: A P
authors.initials: AP
authors.lastname: Alcântara
authors.forename: D
authors.initials: D
authors.lastname: da Matta
authors.forename: M G
authors.initials: MG
authors.lastname: Barberino
authors.forename: S
authors.initials: S
authors.lastname: Bartczak
authors.forename: A L
authors.initials: AL
authors.lastname: Colombo
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology; D000284:Administration, Oral; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002180:Candidiasis, Oral / Q000188:drug therapy*; D015169:Colony Count, Microbial; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012008:Recurrence; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole